DAX ®12.430,88+0,85%TecDAX ®2.816,83-0,28%Dow Jones26.743,50+0,32%NASDAQ 1007.531,07-0,50%

DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018

| Quelle: DGAP | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
BB Biotech AG reports preliminary results for 1H 2018

12-Jul-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Media Release, July 12, 2018
BB Biotech AG reports preliminary results for 1H 2018
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018.
Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.
BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period.
The interim report as of June 30, 2018 will be published on July 20, 2018.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07
Tanja Chicherio, tch@bellevue.ch
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Schwertstrasse 6
8200 Schaffhausen
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX

End of Announcement DGAP News Service

703867  12-Jul-2018 CET/CEST


Passende Hebelprodukte von

WKN Bezeichnung Hebel
XM5QQZ BB BIOTECH WaveUnlimited S 68.111 (DBK) 9,673

Das könnte Sie auch interessieren




Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 39 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen